2. Search Result
Search Result
Results for "

brains

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

3

Fluorescent Dyes

1

Biochemical Assay Reagents

12

Peptides

1

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0265A
    β-Amyloid (1-40) (human) TFA
    5+ Cited Publications

    Amyloid β-Peptide (1-40) (human) TFA; Aβ40 (human) TFA; Aβ(1-40) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease .
    β-Amyloid (1-40) (human) TFA
  • HY-B1122
    L-Cycloserine
    2 Publications Verification

    (S)-Cycloserine; (S)-4-Amino-3-isoxazolidone

    		 GABA Receptor HIV Neurological Disease Cancer
    L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains .
    L-Cycloserine
  • HY-114332
    GNE-8505

    		MAP3K JNK Neurological Disease Metabolic Disease
    GNE-8505 is an orally active, blood-brain barrier-permeable selective dual leucine zipper kinase (DLK) inhibitor. GNE-8505 has an IC50 of 0.144 μM for pJNK, and EC50 of 0.457 μM for DRG. GNE-8505 inhibits the DLK/JNK pathway, reduces stress-induced c-Jun phosphorylation levels, decreases neuronal death and suppresses axonal degeneration. GNE-8505 reduces phosphorylated c-Jun levels in the retina, spinal cord and brain tissues of mice. GNE-8505 is applicable to research related to Alzheimer's disease and amyotrophic lateral sclerosis (ALS) .
    GNE-8505
  • HY-P0265C
    β-Amyloid (1-40), HFIP-treated TFA
    5+ Cited Publications

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-40), HFIP-treated is a β-Amyloid (1-40) (HY-P0265A) treated with HFIP. β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .
    β-Amyloid (1-40), HFIP-treated TFA
  • HY-P1466
    β-Amyloid (1-16)

    Amyloid β-Protein (1-16)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-16)
  • HY-P99185
    Bapineuzumab

    AAB-001

    		 Amyloid-β Neurological Disease
    Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
    Bapineuzumab
  • HY-135714
    Bavarostat

    EKZ-001

    		 HDAC Microtubule/Tubulin Neurological Disease Cancer
    Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent HDAC6 inhibitor and PET radiotracer, with an IC50 as low as 17 nM against human HDAC6. Bavarostat can be labeled with 18F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .
    Bavarostat
  • HY-175748
    MK-7337

    		Radionuclide-Drug Conjugates (RDCs) α-synuclein Neurological Disease
    MK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with 11C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .
    MK-7337
  • HY-135700
    Mevalonolactone

    		Calcineurin Ras HMG-CoA Reductase (HMGCR) Metabolic Disease Inflammation/Immunology
    Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (Ka = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .
    Mevalonolactone
  • HY-P1046
    β-Amyloid (1-15)

    Amyloid β-Protein (1-15)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-15)
  • HY-126031
    (R)-KT109

    		DAGL Inflammation/Immunology
    (R)-KT109 is a peripherally restricted serine hydrolase inhibitor that cannot cross the blood-brain barrier. (R)-KT109 irreversibly inhibits ABHD6, DAGLα and DAGLβ via carbamoylation of the active-site serine. (R)-KT109 exerts selective inhibitory effects on serine hydrolases in mouse brains, with pIC50 values of 8.6, 9.1 and 8.2 against human ABHD6, DAGLα and DAGLβ, respectively. (R)-KT109 effectively reduces the levels of 2-arachidonoylglycerol, arachidonic acid, eicosanoids and TNF-α. (R)-KT109 is widely used in studies of metabolic syndrome-related diseases and neuroinflammation .
    (R)-KT109
  • HY-P1468
    β-Amyloid (1-28)

    Amyloid β-Protein (1-28)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-28)
  • HY-161246
    uPSEM792

    		5-HT Receptor Neurological Disease
    uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM 4-GlyR, with an affinity of Ki of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM 4-GlyR .
    uPSEM792
  • HY-P3780
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)

    		Amyloid-β Neurological Disease
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)
  • HY-P5754B
    TAT-NEP1-40 acetate

    		Apoptosis Neurological Disease
    TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains .
    TAT-NEP1-40 acetate
  • HY-W075176
    Transfluthrin

    		Insecticide Infection
    Transfluthrin is an insecticide with extremely low acute toxicity to vertebrates. Transfluthrin acts as a mosquito repellent, exerts mosquito control effects via electric heating fumigators, and is widely used in studies related to malaria, bancroftian filariasis and mosquito-borne infectious diseases. Transfluthrin may also induce adverse reactions such as pulmonary sensory irritation, sensitization, genotoxicity and respiratory depression, and can increase the concentrations and activities of CYP2E1 and CYP3A2 in rat brains. Transfluthrin can be removed from wastewater through biodegradation and activated sludge adsorption, and can be degraded by microorganisms such as Azovibrio and Tauera .
    Transfluthrin
  • HY-156842
    MCAAD-3

    		Amyloid-β Neurological Disease
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice .
    MCAAD-3
  • HY-P0265AS
    β-Amyloid-15N (1-40) TFA

    Amyloid Beta-Peptide-15N (1-40) (human) TFA; Amyloid β-Peptide-15N (1-40) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid- 15N (1-40) (TFA) is the 15N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .
    β-Amyloid-15N (1-40) TFA
  • HY-174495
    Human EPO mRNA

    		mRNA Others
    Human EPO mRNA encodes the human erythropoietin (EPO) protein, a hormone that controls erythropoiesis, or red blood cell production. EPO also plays a role in wound healing and the brain’s response to neural injury. Kariko et al. showed that transfection of EPO mRNA in vivo resulted in significant increases of both reticulocyte counts and hematocrits.
    Human EPO mRNA
  • HY-158725
    N-Octadecenoyl-(cis-9)-sulfatide

    		Endogenous Metabolite Others
    N-Octadecenoyl-(cis-9) -Sulfatide is a glycolipid found in the brains of mice. N-Octadecenoyl-(cis-9) -Sulfatide can be used as a standard for the determination of C18:13 '-mergogalactosyllactose in dry blood stains of patients with chromatic leukodystrophy (MLD) by ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) .
    N-Octadecenoyl-(cis-9)-sulfatide
  • HY-P5754
    TAT-NEP1-40

    		Apoptosis Neurological Disease
    TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40
  • HY-W075176R
    Transfluthrin (Standard)

    		Insecticide Reference Standards Others
    Transfluthrin (Standard) is the analytical standard of Transfluthrin (HY-W075176). This product is intended for research and analytical applications. Transfluthrin is an insecticide with extremely low acute toxicity to vertebrates. Transfluthrin acts as a mosquito repellent, exerts mosquito control effects via electric heating fumigators, and is widely used in studies related to malaria, bancroftian filariasis and mosquito-borne infectious diseases. Transfluthrin may also induce adverse reactions such as pulmonary sensory irritation, sensitization, genotoxicity and respiratory depression, and can increase the concentrations and activities of CYP2E1 and CYP3A2 in rat brains. Transfluthrin can be removed from wastewater through biodegradation and activated sludge adsorption, and can be degraded by microorganisms such as Azovibrio and Tauera .
    Transfluthrin (Standard)
  • HY-B1122R
    L-Cycloserine (Standard)

    (S)-Cycloserine (Standard); (S)-4-Amino-3-isoxazolidone (Standard)

    		 Reference Standards GABA Receptor HIV Neurological Disease Cancer
    L-Cycloserine (Standard) is the analytical standard of L-Cycloserine. This product is intended for research and analytical applications. L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains[1][2][3][4].
    L-Cycloserine (Standard)
  • HY-W127461
    Ganglioside GM2, Asialo

    Gangliotriosylceramide

    		 Biochemical Assay Reagents Others
    Ganglioside GM2 asialo (asialo-GM2) is a glycosphingolipid containing three monosaccharide residues and one fatty acid of variable chain length, but lacks the sialic acid residue present on ganglioside M2. Asialo-GM2 is found at low or undetectable levels in normal human brains, but it accumulates in the brains of patients with Tay-Sachs disease and Sandhoff disease, which are expressed as lysosomal β- A neurodegenerative disorder characterized by hexosaminidase A and B deficiency. It also binds to various bacteria, including Pseudomonas isolated from cystic fibrosis patients. The Asialo-GM2 mixture contains ganglioside GM2 asialo molecular species with fatty acyl chains of variable length.
    Ganglioside GM2, Asialo
  • HY-P5754A
    TAT-NEP1-40 TFA

    		Apoptosis Neurological Disease
    TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40 TFA
  • HY-P10977
    Tat-ASIC1a (1-20) (mouse, rat)

    		Sodium Channel RIP kinase Neurological Disease
    Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .
    Tat-ASIC1a (1-20) (mouse, rat)
  • HY-167898
    MeS-IMPY

    		Amyloid-β Neurological Disease
    MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [ 11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET) .
    MeS-IMPY
  • HY-P11593
    D-TLKIVWC

    		Tau Protein Neurological Disease
    D-TLKIVWC is a tau fibril disaggregator. D-TLKIVWC has low immunogenicity and anti-degradation properties. D-TLKIVWC disrupts intermolecular hydrogen bonds of tau via a stress-release mechanism. D-TLKIVWC can be used in the research of amyloid diseases such as Alzheimer's disease .
    D-TLKIVWC
  • HY-114239
    JBPOS-0101

    		Amyloid-β Neurological Disease
    JBPOS-0101 is a phenyl carbamate compound. JBPOS-0101 exhibits neuroprotective and antiepileptic effects. JBPOS-0101 can attenuate the accumulation of Aβ in 5XFAD mouse brains and rescue the deficits in learning and memory. JBPOS-0101 can be used for the research of neurological disease, such as Alzheimer's disease (AD) .
    JBPOS-0101
  • HY-W747910A
    S584 dihydrochloride

    		Drug Metabolite Inflammation/Immunology
    S584 dihydrochloride is a catechol metabolite of the oral-effective Piribedil (HY-12707), with anti-lipid peroxidation activity. S584 dihydrochloride significantly inhibits lipid peroxidation in rat synaptosomes under basal conditions and Fe³⁺ stimulation. S584 dihydrochloride significantly antagonizes the increase in thiobarbituric acid reactive substances (TBARS) in the brains of mice exposed to high oxygen and under normal air conditions .
    S584 dihydrochloride
  • HY-181969
    BFB78

    		Virus Protease Infection
    BFB78 is a blood-brain barrier-permeable nsP2 protease inhibitor. BFB78 potently and broadly inhibits the purified nsP2 proteases of various alphaviruses, with IC50 values ranging from 21.6 nM (Mayaro virus; MAYV) to 130.7 nM (Chikungunya virus; CHIKV). BFB78 blocks viral replication in cell culture systems and reduces viral titers in the brains of mice. BFB78 can be used in studies related to Venezuelan equine encephalitis virus (VEEV) infection .
    BFB78
  • HY-117521
    EVP-0015962

    		γ-secretase Amyloid-β Neurological Disease
    EVP-0015962 is an orally active, blood-brain barrier-permeable γ-secretase inhibitor with an IC50 of 3.9 μM. EVP-0015962 alters γ-secretase-mediated cleavage of amyloid precursor protein, reduces Aβ42 production and increases Aβ38 production. EVP-0015962 reduces Aβ aggregates, amyloid plaques and inflammatory markers in the brains of mice, and improves their cognitive impairment. EVP-0015962 can be used for the research of Alzheimer's disease .
    EVP-0015962
  • HY-D3224
    HCP

    		Fluorescent Dye Neurological Disease
    HCP is a two-photon fluorescent probe capable of crossing the blood-brain barrier, which is specifically designed for real-time detection of hypochlorous acid (HClO/ClO -) produced by myeloperoxidase (MPO). Chlorination of the quinoline skeleton of HCP generates HCP-Cl, which eliminates intramolecular charge transfer (ICT) quenching and thereby produces fluorescence. HCP is suitable for in vivo dynamic imaging of HClO in the brains of epileptic mice and high-throughput screening of antiepileptic drugs (HCP-Cl: Ex/Em = 800 nm/495 nm) .
    HCP
  • HY-118807A
    Mepyramine hydrochloride

    Pyrilamine hydrochloride

    		 Histamine Receptor Potassium Channel Neurological Disease Inflammation/Immunology
    Mepyramine hydrochloride (Pyrilamine hydrochloride) is a selective histamine H1 receptor antagonist and KCNQ channel inhibitor, with an IC50 of 12.5 μM against KCNQ2/Q3. Mepyramine hydrochloride shows no activity against allergic asthma in mice when used alone, but modulates the effect of JNJ 7777120 (HY-13508) on allergic asthma in mice; it inhibits the development of morphine physical dependence and increases histamine levels in mouse brains. Mepyramine hydrochloride can be used in studies related to seizures, convulsions, allergic asthma and morphine physical dependence .
    Mepyramine hydrochloride
  • HY-D3171
    AD-BChE/HClO

    		Fluorescent Dye Cholinesterase (ChE) Neurological Disease
    AD-BChE/HClO is a dual-target two-photon fluorescent probe. AD-BChE/HClO can release 4-methylumbelliferone via butyrylcholinesterase-mediated hydrolysis of the ester bond at position 7, as well as hypochlorous acid-mediated thiocarbonyl oxidation. AD-BChE/HClO enables two-photon imaging in nerve cells and mouse brain tissues via tail vein injection. AD-BChE/HClO can be used for the research of Alzheimer's disease .
    AD-BChE/HClO
  • HY-D3226
    Zinc(II) probe-1

    		Fluorescent Dye Neurological Disease
    Zinc (II) probe-1 (Compound DNP) is a dual-color Fluorescent probe that can simultaneously monitor Zn 2+ and H +. Upon interaction with Zn 2+, Zinc (II) probe-1 produces bright blue fluorescence (excitation wavelength: 405 nm; blue channel wavelength: 420-500 nm). Upon interaction with H +, Zinc (II) probe-1 exhibits red fluorescence (excitation wavelength: 561 nm; red channel emission wavelength: 630-730 nm). Zinc (II) probe-1 can be used in studies related to depression .
    Zinc(II) probe-1
  • HY-182366
    EED-IN-5

    		Histone Methyltransferase Neurological Disease Inflammation/Immunology
    EED-IN-5 is an orally active, EZH2-selective trisubstituted pyridine-based EED-H3K27me3 inhibitor and immunomodulator with anti-inflammatory activity. The IC50 value of EED-IN-5 against EED is 28.21 nM. In mouse models, EED-IN-5 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-5 decreases the infiltration of specific dendritic cells, macrophages and T cells into the spinal cord and brain. EED-IN-5 exhibits hERG inhibitory activity, shows negative results in the Mini-Ames test, and causes no obvious toxicity upon long-term high-dose administration. EED-IN-5 can be used for the research of multiple sclerosis .
    EED-IN-5
  • HY-180406
    NPY Y2 antagonist 2

    		Neuropeptide Y Receptor Neurological Disease
    NPY Y2 antagonist 2 is a modulator targeting the neuropeptide Y (NPY) receptor Y2, with pKi values of 6.8 nM and 7.2 nM in human and rat brains, respectively, and demonstrating blood-brain barrier penetration. NPY Y2 antagonist 2 shows selectivity for the Y1 and Y5 receptors. NPY Y2 antagonist 2 blocks the negative feedback regulation mediated by the NPY Y2 receptor, thereby increasing endogenous NPY release and enhancing Y1 receptor activation, resulting in the modulation of central neurotransmitter release. NPY Y2 antagonist 2 exhibits moderate in vivo clearance, high free fraction in rat brain, and a favorable brain/plasma ratio and brain exposure. NPY Y2 antagonist 2 is applicable for research in conditions such as mood disorders, anxiety induced by alcohol withdrawal, and social anxiety associated with nicotine withdrawal .
    NPY Y2 antagonist 2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: